Uloric (Febuxostat) Patent Expiration, LOE Window & CMS Spending

Uloric (Febuxostat) by Takeda: FDA Orange Book LOE 2031-09-08, 12 AB generics, $4.5M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTakeda
FDA Application & PathwayN021856 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2031-09-08
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors12
2024 CMS Total Public Spend$4.5M
2024 Medicare Part D Spend$4.1M
2024 Medicaid Spend$368K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.